AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. The company also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

AstraZeneca Plc adalah perusahaan holding yang bergerak dalam penelitian, pengembangan, produksi, dan komersialisasi obat resep. Perusahaan ini menemukan, mengembangkan, dan mengkomersialkan obat resep di bidang onkologi, penyakit langka, dan biofarmasi, termasuk kardiovaskular, renal dan metabolisme, pernapasan serta imunologi, dan vaksin serta terapi imun. Produk onkologi utama yang dipasarkan meliputi Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex, dan lainnya. Produk penyakit langka meliputi Soliris, Ultomiris, Strensiq, dan Kanuma. Produk biofarmasi mencakup Farxiga, Crestor, Breztri, dan lainnya. Kandidat vaksin investigasi mereka, IVX-A12, menargetkan virus syncytial pernapasan dan metapneumovirus manusia. Kandidat onkologi mereka termasuk FPI-2265 yang menargetkan antigen membran spesifik prostat untuk kanker prostat yang resisten terhadap kastrasi metastatik, yang sedang dalam uji coba Fase II. Perusahaan ini juga menemukan, mengembangkan, dan memproduksi terapi reseptor sel T. Eneboparatide mereka adalah peptida terapeutik investigasi.

Tentang AstraZeneca

Statistik Kunci